The Mercury Tri-Test
Why Our Mercury Tri-Test is Better Than Challenge Testing
- The Challenge Test does not differentiate between MeHg and Hgll. Only Total mercury level is represented (HgT).
- The Challenge Test does not reflect the “pool” of mercury premise.
- There is no “non-challenged” reference range to compare the challenge test; from a regulatory standpoint, there is an obvious potential for over-treatment.
– DMPS has a very different strength and specificity than DMSA.
– IV vs. oral administration has vastly different pharmacokinetics.
– Use of adjuncts such as EDTA, glutathione, and glycine vastly changes the dynamics of the test and its output.
- Lack of standardization of challenge conditions.
– Challenge does not reflect long-term exposure as proven by clinical trial* reference p.120.
– Challenge does not reflect long-term exposure as proven by clinical trial* reference.
- Challenge exposes individual to a large dose of exogenous substance.
- Challenge may cause redistribution of mercury into organs, including the brain.
- Challenge does not measure ambient mercury burden.
- Challenge does not elucidate elimination abilities of the patient.
- Challenge results can be skewed in individuals with renal insufficiency (common in Hgll toxicity).